The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Relapse-free and overall survival in patients with non-seminomatous testicular germ cell tumours with teratoma-free primaries.
 
Pia Paffenholz
No Relationships to Disclose
 
Georg Landwehr
No Relationships to Disclose
 
Christoph Alexander Seidel
No Relationships to Disclose
 
Annika Poch
No Relationships to Disclose
 
Carsten Bokemeyer
Honoraria - AstraZeneca; Bayer; Berlin-Chemie; Bristol-Myers Squibb; Medac; Merck KGaA; Merck Sharp Dohme; Roche; Sanofi
Consulting or Advisory Role - AOK Health Insurance; Bayer Schering Pharma; GSO; Janssen-Cilag GmbH; Merck Sharp & Dohme; Oncology Drug Consult (ODC); Sanofi
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); Agile Therapeutics (Inst); Alexion Pharmaceuticals (Inst); Amgen (Inst); Apellis Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BerGenBio (Inst); BioNTech (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); CPT Cellex Patient Treatment (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Glycostem (Inst); Glycotope GmbH (Inst); immatics (Inst); Incyte (Inst); IO Biotech (Inst); Ipsen (Inst); Isofol Medical (Inst); Janssen-Cilag (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Millennium (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Rafael Pharmaceuticals (Inst); Roche (Inst); Servier/Pfizer (Inst); Springworks Therapeutics (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen-Cilag; Merck Serono; Sanofi
 
Richard Cathomas
Honoraria - Astellas Pharma; Janssen-Cilag
Consulting or Advisory Role - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Janssen-Cilag; MSD Oncology; Pfizer; Roche (Inst); Sanofi (Inst)
 
Pailin Pongratanakul
No Relationships to Disclose
 
Andreas Hiester
No Relationships to Disclose
 
Peter Albers
Honoraria - Bayer; MSD Oncology; Sanofi
Consulting or Advisory Role - MSD Oncology; Roche/Genentech
 
Martin Pichler
No Relationships to Disclose
 
Susanne Krege
No Relationships to Disclose
 
Isabella Syring
No Relationships to Disclose
 
Julia Heinzelbecker
Honoraria - Pierre Fabre; Roche
Travel, Accommodations, Expenses - Ipsen
 
Tim Nestler
Honoraria - Janssen
 
David Pfister
No Relationships to Disclose
 
Axel Heidenreich
Honoraria - Amgen; Astellas Pharma; Bayer; Ferring; Ipsen; Janssen-Cilag; Sanofi; Takeda
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; BMS Global; Clovis Oncology; Janssen-Cilag; MSD Oncology
Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Ipsen; Johnson & Johnson; Pfizer; Sanofi; Takeda
Research Funding - Astellas Pharma; Bayer; BMS Oncology; Sanofi